跳至主要内容
临床试验/ACTRN12622001479796
ACTRN12622001479796尚未招募未知

Diagnostic performance of diffusion-weighted MRI compared to laparoscopy in predicting feasibility of complete cytoreduction in advanced ovarian, fallopian tube and primary peritoneal cancer.

Chris O'Brien Lifehouse (Sydney Local Health District)0 个研究点目标入组 50 人开始时间: 2022年11月24日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
Female

入选标准

  • 1) Age greater than or equal to 18 years old
  • 2) FIGO stage 3 ovarian cancer
  • 3) Histologically or cytologically proven primary epithelial ovarian, primary peritoneal or fallopian tube carcinoma (including serous papillary adenocarcinoma, adenocarcinoma and endometrioid adenocarcinoma)
  • 4) Willingness to provide written informed consent and participate in the study

排除标准

  • 1) Diagnosis other than ovarian cancer
  • 2) Previous abdominal malignancy or tuberculosis
  • 3) Severe claustrophobia
  • 4) MR (magnetic resonance) contrast allergy
  • 5) Hip replacement or spinal hardware
  • 6) Renal failure of either acute or chronic nature which precludes contrast administration

研究者

发起方
Chris O'Brien Lifehouse (Sydney Local Health District)

相似试验